<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708210</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI319A101</org_study_id>
    <nct_id>NCT04708210</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors</brief_title>
  <official_title>An Open-label, Multicenter, Phase Ia/Ib Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of IBI319 in Patients With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, multicenter, phase Ia/Ib study to evaluate the safety, tolerance and&#xD;
      preliminary efficacy of IBI319 in patients with advanced malignant tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">August 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with DLT, AE, treatment-related AE (TRAE), immune-related AEs (irAE), AE of special interest (AESI), serious adverse event (SAE), discontinuation of study drug due to AE, dose-limiting toxicity (DLT) assessed by CTCAE v5.0</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) based on RECIST v1.1 criteria and Lugano 2014 criteria.</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) based on RECIST v1.1 criteria and Lugano 2014 criteria</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) based on RECIST v1.1 criteria and Lugano 2014 criteria</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Response(TTR) based on RECIST v1.1 criteria and Lugano 2014 criteria</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR) based on RECIST v1.1 criteria and Lugano 2014 criteria</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Advanced Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>Phase Ia Dose-Escalation Stage: IBI319</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI319</intervention_name>
    <description>Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.</description>
    <arm_group_label>Phase Ia Dose-Escalation Stage: IBI319</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects able to give voluntary informed consent, understand the study and are willing&#xD;
             to follow and complete all the test procedures.&#xD;
&#xD;
          2. Patients with advanced solid tumors or hematological malignancies who had failed&#xD;
             standard treatment.&#xD;
&#xD;
          3. Male or female subjects ≥18 years and ≤75 years.&#xD;
&#xD;
          4. At least one measurable lesion (per RECIST version 1.1) in solid tumor patients and at&#xD;
             least one measurable and hyper metabolic in 18F-FDG lesion (per Lugano2014) in&#xD;
             lymphoma patients&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.&#xD;
&#xD;
          6. Subjects with life expectancy of ≥ 12 weeks.&#xD;
&#xD;
          7. Subjects must have adequate organ function (liver, kidney function and hematopoietic&#xD;
             function tests) prior IBI319 administration&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.5 x10^9/L&#xD;
&#xD;
               2. Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
               3. Hemoglobin ≥ 9 g / dL (whole blood or component transfusion within 7 days before&#xD;
                  1st dose of study drug is prohibited)&#xD;
&#xD;
               4. Renal function tests: an estimated glomerular filtration rate (eGFR) ≥ 50 mL/min&#xD;
&#xD;
               5. Liver function tests alanine aminotransferase (ALT) and aspartate&#xD;
                  aminotransferase (AST) ≤2.5 x ULN, for patients with known liver cancer or liver&#xD;
                  metastases, AST and ALT ≤ 5 x ULN&#xD;
&#xD;
               6. Total bilirubin (TBil) ≤1.5 x ULN; If Gilbert's Syndrome may have Bilirubin&gt; 2 x&#xD;
                  ULN&#xD;
&#xD;
               7. Coagulation tests: APTT ≤ 1.5 x ULN and INR ≤1.5 x ULN&#xD;
&#xD;
          8. Subjects (males and females) of childbearing potential should be willing to use&#xD;
             reliable contraception methods that are deemed effective by the investigator from&#xD;
             visit 1 through 180 days following the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Legal incapacity or limited legal capacity.&#xD;
&#xD;
          2. Pregnancy, lactation, breastfeeding.&#xD;
&#xD;
          3. Prior treatment with an anti-CD137, anti-Programmed Death Receptor (PD)-1, anti-PD-L1,&#xD;
             anti-PD-L2, anti-Cytotoxic T-Cell Lymphoma-4 Antigen (CTLA-4) antibody, or any other&#xD;
             antibody or drug (except for Ib cohort A and B).&#xD;
&#xD;
          4. NSCLC patients with EGFR mutations or ALK gene rearrangements.&#xD;
&#xD;
          5. Colorectal cancer patients with KRAS mutation / BRAF mutation / HER2 overexpression.&#xD;
&#xD;
          6. Concurrent anticancer treatment or use of other investigational product within 4 weeks&#xD;
             before start of trial treatment; major surgery within 4 weeks before start of trial&#xD;
             treatment (excluding prior diagnostic biopsy).&#xD;
&#xD;
          7. Failure to recover from adverse events from the most recent anti-tumor treatment to&#xD;
             CTCAE ≤ grade 1 or baseline with the exception of alopecia.&#xD;
&#xD;
          8. Acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV)&#xD;
             infection.&#xD;
&#xD;
          9. Subjects with CNS metastasis unless they are asymptomatic or adequately treated with&#xD;
             radiotherapy and/or surgery and subjects are neurologically stable with minimal&#xD;
             residual symptoms/signs.&#xD;
&#xD;
         10. Any other serious underlying medical (e.g., uncontrolled hypertension, active&#xD;
             uncontrolled infection, active gastric ulcer, uncontrolled seizures, cerebrovascular&#xD;
             incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and&#xD;
             clotting disorders, other serious cardiac conditions not listed in exclusion&#xD;
             criteria), psychiatric, psychological, familial or geographical condition that, in the&#xD;
             judgment of the investigator, may interfere with the planned staging, treatment and&#xD;
             follow-up, affect patient compliance or place the patient at high risk from&#xD;
             treatment-related complications.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yilong Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fen Yao</last_name>
    <phone>0512-69566088</phone>
    <email>fen.yao@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yilong Wu</last_name>
      <phone>020-83821484</phone>
      <email>syylwu@live.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

